| Literature DB >> 27583034 |
Emmanuel Sopbue Fondjo1, Djeukoua Dimo Kamal Sorel1, Tamokou Jean-de-Dieu2, Tsemeugne Joseph1, Kouamo Sylvian1, Ngouanet Doriane1, Chouna Jean Rodolphe1, Nkeng-Efouet-Alango Pepin1, Kuiate Jules-Roger2, Ngongang Ndjintchui Arnaud3, Sondengam Beibam Lucas4.
Abstract
The in situ formed 4-oxo-4H-thieno[3,4-c]chromene-3-diazonium sulfate (5) in the coupling reactions involving the parent 2-aminothiophene (4) and various phenolic and arylamines' couplers, readily undergoes homocyclotrimerization at low temperature to afford in fairly good yield the first ever reported eighteen member ring heteroaromatic holigomer 6. Compound 6 was fully characterized by its elemental analysis, IR, UV-Vis, (1)H-NMR, (13)C-NMR and HRMS spectral data. The HMBC and HSQC techniques were used to ascertain the structural assignments. A comparative study on the antimicrobial and antioxidant activities of compounds 3, 4 and 6 was carried out to assess the SAR due to the transformations (from 3 to 6 via 4) on the tested compounds. It was found that compounds 6 and 4 were respectively the most active compounds against bacteria (MIC = 32-64 μg/ml) and yeasts (MIC = 16-64 μg/ml). Compound 6 also showed high radical-scavenging activities and ferric reducing power when compared with vitamin C and BHT used as reference antioxidants.Entities:
Keywords: 2-aminothiophene; Antimicrobial; Antioxidant; Azo compounds; Coumarin; Holigomer; Homocyclotrimerization; SAR
Year: 2016 PMID: 27583034 PMCID: PMC4994106 DOI: 10.2174/1874104501610010021
Source DB: PubMed Journal: Open Med Chem J ISSN: 1874-1045
HSQC and HMBC interactions and 1H and 13C chemical shifts δ in compound 6 in DMSO-d6 as the solvent (25 °C).
| C-atom | δ 13C | HSQC (H→C) | HMBC (H→C) |
|---|---|---|---|
| 6, 20 and 34 | 119.9 | 7.51 (H-8, H-22, H-36) | |
| 14, 28 and 42 | 153.5 | ||
| 1, 15 and 29 | 147.8 | ||
| 13, 27 and 41 | 184.9 | ||
| 11, 25 and 39 | 154.9 | 8.73 (H-7, H-21, H-35), 7.85 (H-9, H-23, H-37), 7.53 (H-10, H-24, H-38) | |
| 10, 24 and 38 | 117.1 | 7.53 (H-10, H-24, H-38) | 7.51 (H-8, H-22, H-36) |
| 9, 23 and 37 | 135.5 | 7.85 (H-9, H-23, H-37) | 8.73 (H-7, H-21, H-35) |
| 8, 22 and 36 | 125.4 | 7.51 (H-8, H-22, H-36) | 7.53 (H-10, H-24, H-38) |
| 7, 21 and 35 | 128.9 | 8.73 (H-7, H-21, H-35) | 7.85 (H-9, H-23, H-37) |
| 4, 18 and 32 | 114.9 | ||
| 5, 19 and 33 | 153.7 |
Antimicrobial activity (MIC and MMC in µg/mL) of compounds 4 and 6 against bacterial and yeast species.
| MIC | 64 | 32 | 64 | 32 | 32 | 64 | 32 | 64 | 64 | 32 | 128 | |
| MMC | 64 | 32 | 64 | 64 | 32 | 64 | 64 | 64 | 64 | 64 | 128 | |
| MMC/MIC | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | |
| MIC | >256 | 32 | >256 | >256 | 64 | >256 | 64 | 32 | 32 | 16 | 64 | |
| MMC | nd | 64 | nd | nd | 64 | nd | 64 | 64 | 32 | 32 | 64 | |
| MMC/MIC | nd | 2 | nd | nd | 1 | nd | 1 | 2 | 1 | 2 | 1 | |
| *Standard drugs | MIC | 8 | 2 | 2 | 2 | 8 | 8 | 1 | 4 | 2 | 4 | 2 |
| MMC | 8 | 4 | 4 | 4 | 8 | 8 | 2 | 4 | 8 | 4 | 4 | |
| MMC/MIC | 1 | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 4 | 1 | 2 |
Compound 3 was not active at concentrations up to 256 μg/ml; nd: not determined; * ciprofloxacin and nystatin were used as standard drugs for bacteria and yeasts respectively; MIC: Minimum inhibitory concentration; MMC: minimum microbicidal concentration; ST: Salmonella typhi ATCC6539; SF: Shigella flexneri ; EF: Enterococcus faecalis ATCC10541; KP: Klebsiella pneumoniae ATCC13883; EC: Escherichia coli ATCC11775; STB: Salmonella paratyphi B; STA: Salmonella paratyphi A ; CPn: Candida parapsilosis; CP: Candida parapsilosis ATCC 22019; CA: Candida albicans ATCC 9002; CG: Candida glabrata IP35.